€10.5 million investment to fund Phase II for new hyperphosphataemia candidate
This article was originally published in Scrip
Executive Summary
Phosphate Therapeutics, a new company with €10.5 million of financing from Inventages Venture Capital, has licensed global rights to PT20, a novel "Phase II ready" phosphate binder for the treatment hyperphosphataemia, from the UK's Medical Research Council (MRC).